6 [55] S. Lehtonen, F. Zhao, and E. Lehtonen, “CD2-associated pro- tein directly interacts with the actin cytoskeleton,” American Journal of Physiology, vol. 283, no. 4, pp. F734–F743, 2002. [56] H. Yuan, E. Takeuchi, and D. J. Salant, “Podocyte slit- diaphragm protein nephrin is linked to the actin cytoskeleton,” American Journal of Physiology, vol. 282, no. 4, pp. F585–F591, 2002. [57] S. Somlo and P. Mundel, “Getting a foothold in nephrotic syndrome,” Nature Genetics, vol. 24, no. 4, pp. 333–335, 2000. [58] J. Henry, M. M. Miller, and P. Pontarotti, “Structure and evolution of the extended B7 family,” Immunology Today, vol. 20, no. 6, pp. 285–288, 1999. [59] C. B. S. Henry and B. R. Duling, “Permeation of the luminal capillary glycocalyx is determined by hyaluronan,” American Journal of Physiology, vol. 277, no. 2, pp. H508–H514, 1999. [60] P. Wakem, R. P. Burns, F. Ramirez et al., “Allergens and irritants transcriptionally upregulate CD80 gene expression in human keratinocytes,” Journal of Investigative Dermatology, vol. 114, no. 6, pp. 1085–1092, 2000. [61] J. Reiser, G. von Gersdorﬀ, M. Loos et al., “Induction of B7-1 in podocytes is associated with nephrotic syndrome,” Journal of Clinical Investigation, vol. 113, no. 10, pp. 1390–1397, 2004. [62] R. Agarwal, “Chronic kidney disease is associated with oxida- tive stress independent of hypertension,” Clinical Nephrology, vol. 61, no. 6, pp. 377–383, 2004. [63] L. Ong-Ajyooth, S. Ong-Ajyooth, and P. Parichatikanond, “The eﬀect of α-tocopherol on the oxidative stress and antioxidants in idiopathic IgA nephropathy,” Journal of the Medical Association of Thailand, vol. 89, supplement 5, pp. S164–S170, 2006. [64] H. T. Kuo, M. C. Kuo, Y. W. Chiu, J. M. Chang, J. Y. Guh, and H. C. Chen, “Increased glomerular and extracellular mal- ondialdehyde levels in patients and rats with focal segmental glomerulosclerosis,” European Journal of Clinical Investigation, vol. 35, no. 4, pp. 245–250, 2005. [65] S. T. Nezhad, B. Momeni, and M. Basiratnia, “Glomerular malondialdehyde levels in patients with focal and segmental glomerulosclerosis and minimal change disease,” Saudi Jour- nal of Kidney Diseases and Transplantation, vol. 21, no. 5, pp. 886–891, 2010. [66] P. Ronco and H. Debiec, “Molecular pathomechanisms of membranous nephropathy: from heymann nephritis to alloimmunization,” Journal of the American Society of Nephrol- ogy, vol. 16, no. 5, pp. 1205–1213, 2005. [67] A. Rees and R. Kain, “A watershed in the understanding of membranous nephropathy,” Nature Reviews Nephrology, vol. 5, no. 11, pp. 617–618, 2009. [68] P. Ronco and H. Debiec, “Membranous glomerulopathy: the evolving story,” Current Opinion in Nephrology and Hypertension, vol. 19, no. 3, pp. 254–259, 2010. [69] M. Nangaku, S. J. Shankland, and W. G. Couser, “Cellular response to injury in membranous nephropathy,” Journal of the American Society of Nephrology, vol. 16, no. 5, pp. 1195– 1204, 2005. [70] P. Ronco and H. Debiec, “Target antigens and nephritogenic antibodies in membranous nephropathy: of rats and men,” Seminars in Immunopathology, vol. 29, no. 4, pp. 445–458, 2007. [71] R. J. Glassock, “The pathogenesis of idiopathic membranous nephropathy: a 50-year odyssey,” American Journal of Kidney Diseases, vol. 56, no. 1, pp. 157–167, 2010. International Journal of Nephrology [72] P. Ronco and H. Debiec, “Podocyte antigens and glomerular disease,” Nephron, vol. 107, no. 2, pp. e41–e46, 2007. [73] J. A. Jeﬀerson, J. W. Pippin, and S. J. Shankland, “Experimental models of membranous nephropathy,” Drug Discovery Today, vol. 7, no. 1-2, pp. 27–33, 2010. [74] C. C. Wu, J. S. Chen, C. F. Huang et al., “Approaching biomarkers of membranous nephropathy from a murine model to human disease,” Journal of Biomedicine and Biotech- nology, vol. 2011, Article ID 581928, 11 pages, 2011. [75] B. J. C. van Damme, G. J. Fleuren, and W. W. Bakker, “Experimental glomerulonephritis in the rat induced by anti- bodies directed against tubular antigens: V. Fixed glomerular antigens in the pathogenesis of heterologous immune complex glomerulonephritis,” Laboratory Investigation, vol. 38, no. 4, pp. 502–510, 1978. [76] W. G. Couser, D. R. Steinmuller, and M. M. Stilmant, “Experimental glomerulonephritis in the isolated perfused rat kidney,” Journal of Clinical Investigation, vol. 62, no. 6, pp. 1275–1287, 1978. [77] J. S. Chen, A. Chen, L. C. Chang et al., “Mouse model of membranous nephropathy induced by cationic bovine serum albumin: antigen dose-response relations and strain diﬀerences,” Nephrology Dialysis Transplantation, vol. 19, no. 11, pp. 2721–2728, 2004. [78] P. Ronco and H. Debiec, “Advances in membranous nephropathy: success stories of a long journey,” Clinical and Experimental Pharmacology and Physiology, vol. 38, no. 7, pp. 410–416, 2011. [79] L. H. Beck Jr., R. G. B. Bonegio, G. Lambeau et al., “M- type phospholipase A2 receptor as target antigen in idiopathic membranous nephropathy,” The New England Journal of Medicine, vol. 361, no. 1, pp. 11–21, 2009. [80] M. Espinosa-Hernandez, R. Ortega-Salas, M. Lo´ pez-Andreu et al., “C4d as a diagnostic tool in membranous nephropathy,” Nefrologia, vol. 32, no. 3, pp. 295–299, 2012.